10x Genomics Inc. Company Profile

Background

Overview

10x Genomics Inc. is a biotechnology company specializing in gene sequencing technologies that enable comprehensive analysis of biological systems. Founded in 2012 by Serge Saxonov, Ben Hindson, and Kevin Ness, the company is headquartered in Pleasanton, California. 10x Genomics offers innovative solutions for single-cell and spatial genomics, facilitating advancements in various fields, including oncology, immunology, and neuroscience.

Mission and Vision

The company's mission is to provide powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology and advance human health. Their vision encompasses enabling researchers to perform detailed analyses of individual cells and tissues, thereby enhancing the understanding of complex biological processes.

Industry Significance

10x Genomics has established itself as a leader in the genomics sector by offering platforms that allow for high-resolution analysis of gene expression and genetic variation. Their technologies have been cited in over 10,000 research papers, underscoring their impact on scientific research and their role in advancing personalized medicine.

Key Strategic Focus

Core Objectives

10x Genomics aims to revolutionize biological research by providing tools that enable comprehensive analysis of cellular and tissue samples. Their focus is on delivering solutions that enhance the understanding of complex diseases and biological systems, thereby accelerating the development of targeted therapies.

Areas of Specialization

The company specializes in single-cell genomics, spatial transcriptomics, and in situ analysis. These areas allow researchers to examine gene expression and genetic variation at unprecedented resolutions, facilitating insights into cellular heterogeneity and tissue architecture.

Key Technologies Utilized

Chromium Platform: Enables single-cell analysis through microfluidic chips and related consumables.

Visium Spatial Platform: Facilitates spatial gene expression analysis.

Xenium In Situ: Allows for direct detection and preservation of RNA targets within tissue sections.

Primary Markets Targeted

10x Genomics primarily serves academic and translational researchers, as well as biopharmaceutical companies, providing them with tools to conduct high-resolution genomic analyses.

Financials and Funding

Funding History

Since its inception, 10x Genomics has secured substantial funding to support its growth and technological advancements. Notable funding rounds include:

Series B (January 2015): Raised $55.5 million led by Foresite Capital Management.

Series C (March 2016): Secured $55 million led by Fidelity Management & Research.

Series D (April 2018): Raised $125 million led by Meritech Capital Partners.

Series D (January 2019): Secured an additional $35 million led by Meritech Capital Partners.

Recent Financial Performance

In 2023, 10x Genomics reported revenues of $610.8 million, reflecting a 1.3% decrease compared to the previous year. The company has demonstrated consistent growth, with revenues increasing from $3.32 million in 2015 to $618.7 million in 2023.

Pipeline Development

Key Pipeline Candidates

10x Genomics continues to innovate in the field of genomics, with a focus on enhancing the capabilities of its existing platforms and developing new applications to address complex biological questions. Specific details regarding pipeline candidates and development stages are proprietary and not publicly disclosed.

Technological Platform and Innovation

Proprietary Technologies

Chromium Single Cell Platform: Allows for high-throughput single-cell analysis, enabling the study of gene expression and genetic variation at the individual cell level.

Visium Spatial Gene Expression: Provides spatial context to gene expression data, facilitating the understanding of tissue architecture and cellular interactions.

Xenium In Situ: Enables direct detection and preservation of RNA targets within tissue sections, offering insights into gene expression within the tissue microenvironment.

Significant Scientific Methods

The company employs advanced microfluidics, biochemistry, and computational biology techniques to develop its platforms. These methodologies allow for the integration of hardware, chemistry, and software to provide comprehensive genomic analyses.

Leadership Team

Key Executives

Serge Saxonov: Co-founder and CEO. Serge has a background in computational biology and previously served as the founding architect and director of research and development at 23andMe.

Ben Hindson: Co-founder and President. Ben has extensive experience in genomics and has held leadership roles in various biotechnology companies.

Adam S. Taich: Chief Financial Officer. Adam joined 10x Genomics in 2024, bringing experience from previous roles in the biotechnology sector.

Michael Schnall-Levin: Chief Technology Officer. Michael leads the company's technological strategy and development efforts.

Competitor Profile

Market Insights and Dynamics

The genomics market is characterized by rapid technological advancements and increasing demand for high-resolution biological analyses. Key trends include the integration of spatial information into genomic studies and the development of single-cell analysis techniques.

Competitor Analysis

10x Genomics faces competition from several companies in the genomics and biotechnology sectors, including:

Illumina Inc.: A leading provider of sequencing and array-based solutions for genetic analysis.

Pacific Biosciences of California Inc.: Specializes in long-read sequencing technologies.

Mission Bio: Focuses on single-cell DNA analysis.

Strategic Collaborations and Partnerships

In August 2025, 10x Genomics entered into an agreement to acquire Scale Biosciences, Inc., a pharmaceutical company, to enhance its capabilities in spatial genomics.

Operational Insights

10x Genomics maintains a competitive edge through its comprehensive product offerings, including the Chromium and Visium platforms, which provide integrated solutions for single-cell and spatial genomics. The company's focus on innovation and customer support further strengthens its market position.

Strategic Opportunities and Future Directions

The company is well-positioned to capitalize on the growing demand for spatial and single-cell genomic analyses. Future opportunities include expanding applications in personalized medicine, enhancing platform capabilities, and exploring new market segments.